An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients.

NCT01839552 | Withdrawn Phase 4 DMC

• 1 other identifier: BCC-CA-12
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Lazanda is a prescription nasal spray medicine that contains the medicine fentanyl. It is used to manage breakthrough pain in adults with cancer who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Lazanda is started only after taking other opioid pain medicines and the patient's body has become used to them (opioid tolerant). The purpose of this study is to assess the ability of Lazanda to control pain during an episode of breakthrough pain in cancer patients.

Conditions

Pain

Keywords

Fentanyl Citrate Nasal Spray (FCNS); Lazanda; Breakthrough pain in cancer patients

Outcome Measures

Primary Outcomes (1)

• Pain Intensity

  The primary efficacy outcome measure is pain intensity difference at 15 minutes (PID15) after dosing during the Maintenance Stage. (PID15 is defined as the difference between pain intensity at 15 minutes and baseline.)Maintenance stage is defined as 6 breakthrough pain episodes for up to 6 weeks.

  Assessed at end of Maintenance Stage

Secondary Outcomes (1)

• Pain Management Satisfaction

  participants will be followed during maintenance phase, up to 6 weeks

Study Arms (1)

Fentanyl Citrate Nasal Spray (FCNS)

EXPERIMENTAL

Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)

Drug: Fentanyl Citrate Nasal Spray (FCNS)

Interventions

Fentanyl Citrate Nasal Spray (FCNS) DRUG

Also known as: Lazanda

Fentanyl Citrate Nasal Spray (FCNS)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who meet the following criteria will be eligible:
• At least 18 years of age or older.
• Diagnosed with cancer.
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Patients with cancer who are experiencing episodes of BTPc in spite of optimized background analgesia with at least 60 mg/day of morphine (or equivalent analgesic) for at least 7 days.
• Patients with cancer currently using an SAO (short acting opioid) to manage their episodes of BTPc.
• Patients with cancer who have failed to obtain a timely response, as determined by the Principal Investigator, to pain from their SAO therapy.
• Laboratory values consistent with the stage of disease that are deemed clinically insignificant by the investigator.
• Female patients of child bearing potential or male patients with partners of child bearing potential who are using an adequate form of contraception before study entry, and agree to use an adequate form of contraception for an additional month after the study. Adequate contraception is defined as the use of any hormonal contraception or intra-uterine device by the female patient/partner plus use by at least 1 of the partners of an additional spermicide-containing barrier method of contraception. The use of a barrier method alone or abstinence is not considered adequate.
• Willing and able to give written informed consent before participating in the study.

You may not qualify if:

• Patients meeting the following criteria will be excluded from the study:
• Patients who are not opioid tolerant.
• Patients with a known intolerance or hypersensitivity to fentanyl.
• Physical abnormalities of the nose that could affect nasal absorption.
• Patients with uncontrolled or rapidly escalating pain.
• Patients with a history of alcohol or substance abuse.
• A clinically significant medical history (past or present) of any disease that would compromise the study or the well-being of the patient .
• Patients who have participated in another clinical trial with an analgesic within the last month.
• Patients who have previously used FCNS and did not have adequate responses.
• Female patients with a positive pregnancy test or who are currently lactating.
• Patients who are taking medications that are known inhibitors of the CYP3A4 isoenzyme, such as ketoconazole.
• Patients who have taken a monoamine oxidase inhibitor within 14 days before a dose of study medication.

Sponsors & Collaborators

• University of Louisville: lead
• James Graham Brown Cancer Center: collaborator

Study Sites (1)

James Graham Brown Cancer Center

Louisville, Kentucky, 40202, United States

Location

MeSH Terms

Conditions

Pain

Interventions

Fentanyl

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Goetz Kloecker, MD, FACP, MBA, MSPH

  James Graham Brown Cancer Center-University of Louisville

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: April 10, 2013
• First Posted: April 25, 2013
• Study Start: October 1, 2014
• Primary Completion: April 1, 2017
• Study Completion: April 1, 2018
• Last Updated: March 5, 2018

Record last verified: 2018-03

Locations

US (1)